Severe Aortic Valve Stenosis Clinical Trial
Official title:
Cerebral Protection in Transcatheter Aortic Valve Replacement: The PROTEMBO Trial
The goal of this prospective, multi-center, randomized, controlled study is to compare the safety and efficacy of the ProtEmbo Cerebral Embolic Protection device to a hybrid control (no embolic protection device ('No Device') and the Sentinel device) in subjects with severe symptomatic native aortic valve stenosis indicated undergoing a TAVR procedure.
Subjects with severe symptomatic aortic stenosis undergoing TAVR will be able to participate. Participants will be randomized in a 2:1:1 fashion to either the ProtEmbo arm, the Sentinel arm, or the 'No device' arm. Enrolled subjects will undergo an MRI at baseline and at 36 hours ±12 hours, to evaluate any new cerebral lesions. Enrolled subjects will be followed for 30 days. The study aims to address: - whether the occurrence of all Major Adverse Cardiac and Cerebrovascular Events (MACCE) at 30 days is comparable between the ProtEmbo group and the hybrid control group. - whether the total new lesion volume in the brain assessed by diffusion weighted magnetic resonance images at 36 ±12 hours is comparable between the ProtEmbo group and the hybrid control group. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05552352 -
VRAP-Heart - Virtual Reality Assisted Patient Empowerment for Interventions in Structural Heart Disease
|
N/A | |
Recruiting |
NCT06168123 -
Future Optimal Research and Care Evaluation - Aortic Stenosis
|
||
Active, not recruiting |
NCT05182307 -
DurAVRâ„¢ THV System: First-In-Human Study
|
N/A | |
Recruiting |
NCT06156592 -
Post Spinal Hemodynamic Changes in Aortic Stenosis and Mitral Regurgitation by VIS Index and Echocardiography
|
||
Completed |
NCT04259723 -
Virtual Reality Assisted Conscious Sedation During TAVI
|
N/A | |
Recruiting |
NCT04128384 -
Infranodal Conduction Time During TAVR as Predictor of HAVB
|
N/A | |
Recruiting |
NCT05024942 -
LUS in Aortic Stenosis Patients Undergoing TAVR
|
||
Recruiting |
NCT05283356 -
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
|
Phase 4 | |
Not yet recruiting |
NCT05847751 -
The Use of ACURATE Neo 2 Valve in Patients With Symptomatic Aortic Valve Stenosis
|
||
Completed |
NCT02224066 -
Platelet Reactivity After TAVI: A Multicenter Pilot Study
|
Phase 4 | |
Recruiting |
NCT06168370 -
Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation
|
N/A | |
Recruiting |
NCT05097183 -
Validation of Accurate Commissural Alignment During Transcatheter Aortic Valve Implantation
|
||
Active, not recruiting |
NCT05712161 -
Use of DurAVRâ„¢ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
|
N/A | |
Not yet recruiting |
NCT04988243 -
Multi Center Registry of Transcatheter Aortic Valve Replacement in Northeast China
|
N/A |